Regulatory News has published 1 story about Sling Therapeutics on 20 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 20 September 2026.
This page is generated from Regulatory News’ editorial coverage of Sling Therapeutics. It is not an advertisement.
On the record
- Company
- Sling Therapeutics, Inc.
- Headquarters
- Ann Arbor, Michigan
- Founded
- Launched publicly in June 2022 with a $35 million Series A
- Regulator
- U.S. Food and Drug Administration (linsitinib holds Fast Track designation)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
